Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update

26th January 2017 - 4:17 pm

Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the keys points to take away from this update.


Share this article